B. Riley upgraded Cognition Therapeutics (CGTX) to Buy from Neutral with a $1.50 price target
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CGTX:
- Cognition Therapeutics price target raised to $6 from $5 at H.C. Wainwright
- Cognition Therapeutics announces results in Phase 2 study of CT1812
- Cognition announces all participants completed final visit in SHIMMER study
- Cognition Therapeutics provided an update on Phase 2 ‘SHINE’ study analysis
- Cognition Therapeutics Reports Promising Q3 2024 Results